Cargando…

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy

Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, sugg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferla, Valeria, Antonini, Elena, Perini, Tommaso, Farina, Francesca, Masottini, Serena, Malato, Simona, Marktel, Sarah, Lupo Stanghellini, Maria Teresa, Tresoldi, Cristina, Ciceri, Fabio, Marcatti, Magda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426755/ https://www.ncbi.nlm.nih.gov/pubmed/36052251 http://dx.doi.org/10.3389/fonc.2022.932852

Ejemplares similares

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
por: Farina, Francesca, et al.
Publicado: (2023)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
por: Farina, Francesca, et al.
Publicado: (2022)

P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA
por: Perini, Tommaso, et al.
Publicado: (2023)

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
por: Liberatore, Carmine, et al.
Publicado: (2023)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
por: Farina, Francesca, et al.
Publicado: (2023)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma
por: Di Lullo, Giulia, et al.
Publicado: (2019)

A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
por: Milan, Enrico, et al.
Publicado: (2015)

Following-up allogeneic transplantation recipients during the COVID-19 pandemic
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2020)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival
por: Di Lullo, Giulia, et al.
Publicado: (2015)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients
por: Serpenti, Fabio, et al.
Publicado: (2021)

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial
por: Lazzari, Lorenzo, et al.
Publicado: (2021)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
por: Xue, Elisabetta, et al.
Publicado: (2022)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Improving the safety of cell therapy with the TK-suicide gene
por: Greco, Raffaella, et al.
Publicado: (2015)

Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation
por: Raffaella, Greco, et al.
Publicado: (2019)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
por: Sannipoli, Daniele, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment
por: Belloni, Daniela, et al.
Publicado: (2018)

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
por: Nandakumar, B., et al.
Publicado: (2022)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3uamk79uebf8lk8klhhh6huhlo